09 Jan2019
03 Jan2019
SQZ Biotech Strengthens Leadership Team with Appointment of Chief Medical Officer
Industry veteran, Oliver Rosen, MD, to join executive team as SQZ prepares to enter the clinic WATERTOWN, Mass., Jan. 3, 2019 –- SQZ Biotechnologies (SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced the appointment of Oliver Rosen, MD, as Chief Medical Officer. Dr. Rosen will oversee the clinical development of SQZ’s cell therapy pipeline and joins the company as it prepares to enter the clinic with a lead oncology candidate.
19 Nov2018
SQZ Biotech pushes forward with its method to squeeze drugs into cells
One Watertown, Mass.-based biotech is working to capitalize on growing momentum for cell and gene therapies — and it seems to have found its opening. READ MORE
15 Oct2018
SQZ Biotech Expands Cell Therapy Partnership with Roche to Develop Antigen Presenting Cells for Immune-Oncology
- Collaboration combines SQZ Biotech’s novel cell therapy platform with Roche´s cancer immunotherapy expertise
- SQZ to receive up to $125 million in upfront and near-term milestone payments
16 Nov2017